14 results on '"Wenzel, Hans H. B."'
Search Results
2. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study
- Author
-
Schuurman, Teska N, Schaafsma, Mirte, To, Kaylee H, Verhoef, Viola M J, Sikorska, Karolina, Siebers, Albert G, Wenzel, Hans H B, Bleeker, Maaike C G, Roes, Eva Maria, Zweemer, Ronald P, de Vos van Steenwijk, Peggy J, Yigit, Refika, Beltman, Jogchum J, Zusterzeel, Petra L M, Lok, Christianne A R, Bekkers, Ruud L M, Mom, Constantijne H, and van Trommel, Nienke E
- Published
- 2023
- Full Text
- View/download PDF
3. The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases—a literature review
- Author
-
Olthof, Ester P., van der Aa, Maaike A., Adam, Judit A., Stalpers, Lukas J. A., Wenzel, Hans H. B., van der Velden, Jacobus, and Mom, Constantijne H.
- Published
- 2021
- Full Text
- View/download PDF
4. Treatment Strategies Guided by [18F]FDG-PET/CT in Patients with Locally Advanced Cervical Cancer and [18F]FDG-Positive Lymph Nodes.
- Author
-
Olthof, Ester P., Wenzel, Hans H. B., van der Velden, Jacobus, Stalpers, Lukas J. A., Mom, Constantijne H., and van der Aa, Maaike A.
- Subjects
- *
METASTASIS , *POSITRON emission tomography computed tomography , *LYMPH nodes , *RETROSPECTIVE studies , *CHEMORADIOTHERAPY , *COMPARATIVE studies , *RADIOPHARMACEUTICALS , *DESCRIPTIVE statistics , *RESEARCH funding , *DEOXY sugars , *CYTOREDUCTIVE surgery ,CERVIX uteri tumors - Abstract
Simple Summary: Current guidelines recommend treatment planning using [18F]FDG-PET/CT for the management of advanced cervical cancer, where suspicious lymph nodes may be treated with nodal boosting, extended-field radiotherapy, and/or debulking in addition to standard chemoradiotherapy to improve survival. However, caution must be exercised because of the risk of unnecessary therapy-related toxicity due to the overtreatment of false-positive nodes. Despite this daily dilemma in clinical practice, only a few studies have evaluated the management of [18F]FDG-positive nodes. Therefore, this study aimed to assess how often [18F]FDG-PET/CT lymph node information is used in the management of advanced-stage cervical cancer. We found that a total of 380/434 patients (88%) received interventions targeting [18F]FDG-positive nodes, with the following distribution: nodal boosting (84%), extended-field radiotherapy (78%), and debulking (12%). Despite existing guidelines advocating [18F]FDG-PET/CT-guided treatment planning for the management of advanced cervical cancer, this study highlights that not all cases of [18F]FDG-positive nodes received an intervention. Background: Modern treatment guidelines for women with advanced cervical cancer recommend staging using 2-deoxy-2-[18F]fluoro-D-glucose positron emission computed tomography ([18F]FDG-PET/CT). However, the risk of false-positive nodes and therapy-related adverse events requires caution in treatment planning. Using data from the Netherlands Cancer Registry (NCR), we estimated the impact of [18F]FDG-PET/CT on treatment management in women with locally advanced cervical cancer, i.e., on nodal boosting, field extension, and/or debulking in cases of suspected lymph nodes. Methods: Women diagnosed between 2009 and 2017, who received chemoradiotherapy for International Federation of Gynaecology and Obstetrics (2009) stage IB2, IIA2-IVB cervical cancer with an [18F]FDG-positive node, were retrospectively selected from the NCR database. Patients with pathological nodal examination before treatment were excluded. The frequency of nodal boosting, extended-field radiotherapy, and debulking procedures applied to patients with [18F]FDG-positive lymph nodes was evaluated. Results: Among the 434 eligible patients with [18F]FDG-positive nodes, 380 (88%) received interventions targeting these lymph nodes: 84% of these 380 patients received nodal boosting, 78% extended-field radiotherapy, and 12% debulking surgery. [18F]FDG-positive nodes in patients receiving these treatments were more likely to be classified as suspicious than inconclusive (p = 0.009), located in the para-aortic region (p < 0.001), and larger (p < 0.001) than in patients who did not receive these treatments. Conclusion: While existing guidelines advocate [18F]FDG-PET/CT-guided treatment planning for the management of advanced cervical cancer, this study highlights that not all cases of [18F]FDG-positive nodes received an intervention, possibly due to the risk of false-positive results. Improvement of nodal staging may reduce suboptimal treatment planning. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Survival of Women with Advanced Stage Cervical Cancer: Neo-Adjuvant Chemotherapy Followed by Radiotherapy and Hyperthermia versus Chemoradiotherapy.
- Author
-
Servayge, Jonathan, Olthof, Ester P., Mom, Constantijne H., van der Aa, Maaike A., Wenzel, Hans H. B., van der Velden, Jacobus, Nout, Remi A., Boere, Ingrid A., van Doorn, Helena C., and van Beekhuizen, Heleen J.
- Subjects
KRUSKAL-Wallis Test ,FEVER ,CONFIDENCE intervals ,LYMPHADENECTOMY ,CANCER chemotherapy ,MULTIVARIATE analysis ,MULTIPLE regression analysis ,ONE-way analysis of variance ,TUMOR classification ,CHEMORADIOTHERAPY ,PSYCHOLOGY of women ,CHI-squared test ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,CERVIX uteri tumors ,COMBINED modality therapy ,PROGRESSION-free survival ,DATA analysis software ,OVERALL survival ,PROPORTIONAL hazards models ,EVALUATION - Abstract
Simple Summary: Women with locally advanced cervical cancer and nodal involvement remain a prognostically unfavourable group. Concurrent chemoradiation is considered standard treatment; however, alternative treatments have been investigated. Our main objective was to investigate overall survival and disease-free survival in triple therapy in locally advanced cervical cancer with nodal involvement. Furthermore, we wanted to compare triple therapy to standard chemoradiotherapy in a patient cohort with the same inclusion criteria. We included women with a tumour size of ≥6 cm, and/or pelvic lymph node metastasis of ≥2 cm and/or para-aortic lymph node metastasis of ≥1 cm. In our cohort of 370 patients, toxicity and survival of triple therapy is similar to chemoradiation with or without prior lymph node debulking. These findings suggest a role for hyperthermia in the management of locally advanced cervical cancer and could offer patients with nodal involvement an alternative treatment option. Aim: To investigate and compare overall survival (OS), disease-free survival (DFS) and toxicity of women who underwent either chemoradiotherapy with or without prior lymph node debulking or upfront chemotherapy followed by radiotherapy and hyperthermia (triple therapy) for locally advanced cervical cancer (LACC) to identify a potential role for triple therapy. Methods: Women with histologically proven LACC and with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB2 and IIA2 to IVA were included. Cox regression analyses were used for calculating hazard ratios and to adjust for confounding variables. A multivariable logistic regression analysis was used to examine the influence of covariates on toxicity. Results: A total of 370 patients were included of whom 58% (n = 213) received chemoradiotherapy (CRT), 18% (n = 66) received node-debulking followed by chemoradiotherapy (LND-CRT) and 25% (n = 91) received triple therapy (TT). Five-year OS was comparable between the three treatment groups, with 53% (95% confidence interval 46–59%) in the CRT group, 45% (33–56%) in the LND-CRT group and 53% (40–64%) in the TT group (p = 0.472). In the adjusted analysis, 5-year OS and DFS were comparable between the three treatment groups. No chemotherapy-related differences in toxicity were observed. Conclusion: This study suggests that the toxicity and survival of TT is similar to CRT or LND-CRT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Stage, treatment and survival of low‐grade serous ovarian carcinoma in the Netherlands: A nationwide study.
- Author
-
De Decker, Koen, Wenzel, Hans H. B., Bart, Joost, van der Aa, Maaike A., Kruitwagen, Roy F. P. M., Nijman, Hans W., and Kruse, Arnold‐Jan
- Subjects
- *
OVARIAN epithelial cancer , *POISSON regression , *CARCINOMA , *SURVIVAL rate - Abstract
Introduction: Serous ovarian carcinomas constitute the largest group of epithelial ovarian cancer (60%–75%) and are further classified into high‐ and low‐grade serous carcinoma. Low‐grade serous carcinoma (LGSC) is a relatively rare subtype (approximately 5% of serous carcinomas) and epidemiologic studies of large cohorts are scarce. With the present study we aimed to report trends in stage, primary treatment and relative survival of LGSC of the ovary in a large cohort of patients in an effort to identify opportunities to improve clinical practice and outcome of this relatively rare disease. Material and Methods: Patients diagnosed with LGSC between 2000 and 2019 were identified from the Netherlands Cancer Registry (n = 855). Trends in FIGO stages and primary treatment were analyzed with the Cochran–Armitage trend test, and differences in and trends of 5‐year relative survival were analyzed using multivariable Poisson regression. Results: Over time, LGSC was increasingly diagnosed as stage III (39.9%–59.0%) and IV disease (5.7%–14.4%) and less often as stage I (34.6%–13.5%; p < 0.001). Primary debulking surgery was the most common strategy (76.2%), although interval debulking surgery was preferred more often over the years (10.6%–31.1%; p < 0.001). Following primary surgery, there was >1 cm residual disease in only 15/252 patients (6%), compared with 17/95 patients (17.9%) after interval surgery. Full cohort 5‐year survival was 61% and survival after primary debulking surgery was superior to the outcome following interval debulking surgery (60% vs 34%). Survival following primary debulking surgery without macroscopic residual disease (73%) was better compared with ≤1 cm (47%) and >1 cm residual disease (22%). Survival following interval debulking surgery without macroscopic residual disease (51%) was significantly higher than after >1 cm residual disease (24%). Except FIGO stage II (85%–92%), survival did not change significantly over time. Conclusions: Over the years, LGSC has been diagnosed as FIGO stage III and stage IV disease more often and interval debulking surgery has been increasingly preferred over primary debulking in these patients. Relative survival did not change over time (except for stage II) and worse survival outcomes after interval debulking surgery were observed. The results support the common recommendation to perform primary debulking surgery in patients eligible for primary surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Does the New FIGO 2018 Staging System Allow Better Prognostic Differentiation in Early Stage Cervical Cancer? A Dutch Nationwide Cohort Study.
- Author
-
Ten Eikelder, Mieke L. G., Hinten, Floor, Smits, Anke, Van der Aa, Maaike A., Bekkers, Ruud L. M., IntHout, Joanna, Wenzel, Hans H. B., and Zusterzeel, Petra L. M.
- Subjects
RISK of metastasis ,LYMPHOMA risk factors ,CONFIDENCE intervals ,ONE-way analysis of variance ,MULTIPLE regression analysis ,MULTIVARIATE analysis ,RETROSPECTIVE studies ,TUMOR classification ,CANCER patients ,SURVIVAL analysis (Biometry) ,KAPLAN-Meier estimator ,CHI-squared test ,CERVIX uteri tumors ,LOGISTIC regression analysis ,ODDS ratio ,DATA analysis software ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
Simple Summary: The introduction of a revised staging system (FIGO 2018 staging system) for cervical cancer has led to a significant change in stage allocation for patients with early stage disease. It remains unclear how this change should be translated into treatment options, including less extensive surgery. With this Dutch national study we evaluated whether the revised staging system resulted in a more accurate prediction of overall and recurrence free survival compared to the previous FIGO 2009 staging system. In addition, we assessed other factors which may help the paradigm of treatment. We concluded that the revised FIGO 2018 staging system gives a more precise indication of survival outcomes of women with early stage cervical cancer. In addition, we believe that aside from stage, tumor characteristics, such as LVSI, and depth of invasion should be considered when offering patients less radical or less extensive treatment. The FIGO 2018 staging system was introduced to allow better prognostic differentiation in cervical cancer, causing considerable stage migration and affecting treatment options. We evaluated the accuracy of the FIGO 2018 staging in predicting recurrence free (RFS) and overall survival (OS) compared to FIGO 2009 staging in clinically early stage cervical cancer. We conducted a nationwide retrospective cohort study, including 2264 patients with preoperative FIGO (2009) IA1, IA2 and IB1 cervical cancer between 2007–2017. Kaplan–Meier analyses were used to assess survival outcomes. Logistic regression was used to assess risk factors for lymph node metastasis and parametrial invasion. Stage migration occurred in 48% (22% down-staged, 26% up-staged). Survival data of patients down-staged from IB to IA1/2 disease were comparable with FIGO 2009 IA1/2 and better than patients remaining stage IB1. LVSI, invasion depth and parametrial invasion were risk factors for lymph node metastases. LVSI, grade and age were associated with parametrial invasion. In conclusion, the FIGO 2018 staging system accurately reflects prognosis in early stage cervical cancer and is therefore more suitable than the FIGO 2009 staging. However subdivision in IA1 or IA2 based on presence or absence of LVSI instead of depth of invasion would have improved accuracy. For patients down-staged to IA1/2, less radical surgery seems appropriate, although LVSI and histology should be considered when determining the treatment plan. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. The prognostic value of the number of positive lymph nodes and the lymph node ratio in early‐stage cervical cancer.
- Author
-
Olthof, Ester P., Mom, Constantijne H., Snijders, Malou L. H., Wenzel, Hans H. B., van der Velden, Jacobus, and van der Aa, Maaike A.
- Abstract
Introduction: To establish the impact of the number of lymph node metastases (nLNM) and the lymph node ratio (LNR) on survival in patients with early‐stage cervical cancer after surgery. Material and methods: In this nationwide historical cohort study, all women diagnosed between 1995 and 2020 with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IA2–IIA1 cervical cancer and nodal metastases after radical hysterectomy and pelvic lymphadenectomy from the Netherlands Cancer Registry were selected. Optimal cut‐offs for prognostic stratification by nLNM and LNR were calculated to categorize patients into low‐risk or high‐risk groups. Kaplan–Meier overall survival analysis and flexible parametric relative survival analysis were used to determine the impact of nLNM and LNR on survival. Missing data were imputed. Results: The optimal cut‐off point was ≥4 for nLNM and ≥0.177 for LNR. Of the 593 women included, 500 and 501 (both 84%) were categorized into the low‐risk and 93 and 92 (both 16%) into the high‐risk groups for nLNM and LNR, respectively. Both high‐risk groups had a worse 5‐year overall survival (p < 0.001) compared with the low‐risk groups. Being classified into the high‐risk groups is an independent risk factor for relative survival, with excess hazard ratios of 2.4 (95% confidence interval 1.6–3.5) for nLNM and 2.5 (95% confidence interval 1.7–3.8) for LNR. Conclusions: Presenting a patient's nodal status postoperatively by the number of positive nodes, or by the nodal ratio, can support further risk stratification regarding survival in the case of node‐positive early‐stage cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Short-term surgical complications after radical hysterectomy-A nationwide cohort study.
- Author
-
Wenzel, Hans H. B., Kruitwagen, Roy F. P. M., Nijman, Hans W., Bekkers, Ruud L. M., Gorp, Toon, Kroon, Cornelis D., Lonkhuijzen, Luc R. C. W., Massuger, Leon F. A. G., Smolders, Ramon G. V., Trommel, Nienke E., Yigit, Refika, Zweemer, Ronald P., Aa, Maaike A., van Gorp, Toon, de Kroon, Cornelis D, van Lonkhuijzen, Luc R C W, van Trommel, Nienke E, and van der Aa, Maaike A
- Subjects
- *
SURGICAL complications , *LYMPHADENECTOMY , *TRACHELECTOMY , *HYSTERECTOMY , *BODY mass index , *LOGISTIC regression analysis , *COHORT analysis , *ACQUISITION of data , *LONGITUDINAL method , *SURGICAL excision , *LYMPH node surgery ,CERVIX uteri tumors - Abstract
Introduction: Centralization has, among other aspects, been argued to have an impact on quality of care in terms of surgical morbidity. Next, monitoring quality of care is essential in identifying areas of improvement. This nationwide cohort study was conducted to determine the rate of short-term surgical complications and to evaluate its possible predictors in women with early-stage cervical cancer.Material and Methods: Women diagnosed with early-stage cervical cancer, 2009 FIGO stages IB1 and IIA1, between 2015 and 2017 who underwent radical hysterectomy with pelvic lymphadenectomy in 1 of the 9 specialized medical centers in the Netherlands, were identified from the Netherlands Cancer Registry. Women were excluded if primary treatment consisted of hysterectomy without parametrial dissection or radical trachelectomy. Women in whom radical hysterectomy was aborted during the procedure, were also excluded. Occurrence of intraoperative and postoperative complications and type of complications, developing within 30 days after surgery, were prospectively registered. Multivariable logistic regression analysis was used to identify predictors of surgical complications.Results: A total of 472 women were selected, of whom 166 (35%) developed surgical complications within 30 days after radical hysterectomy. The most frequent complications were urinary retention with catheterization in 73 women (15%) and excessive perioperative blood loss >1000 mL in 50 women (11%). Open surgery (odds ratio [OR] 3.42; 95% CI 1.73-6.76), chronic pulmonary disease (OR 3.14; 95% CI 1.45-6.79), vascular disease (OR 1.90; 95% CI 1.07-3.38), and medical center (OR 2.83; 95% CI 1.18-6.77) emerged as independent predictors of the occurrence of complications. Body mass index (OR 0.94; 95% CI 0.89-1.00) was found as a negative predictor of urinary retention. Open surgery (OR 36.65; 95% CI 7.10-189.12) and body mass index (OR 1.15; 95% CI 1.08-1.22) were found to be independent predictors of excessive perioperative blood loss.Conclusions: Short-term surgical complications developed in 35% of the women after radical hysterectomy for early-stage cervical cancer in the Netherlands, a nation with centralized surgical care. Comorbidities predict surgical complications, and open surgery is associated with excessive perioperative blood loss. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
10. A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
- Author
-
Wenzel HHB, Hardie AN, Moncada-Torres A, Høgdall CK, Bekkers RLM, Falconer H, Jensen PT, Nijman HW, van der Aa MA, Martin F, van Gestel AJ, Lemmens VEPP, Dahm-Kähler P, Alfonzo E, Persson J, Ekdahl L, Salehi S, Frøding LP, Markauskas A, Fuglsang K, and Schnack TH
- Subjects
- Female, Humans, Lymphatic Metastasis pathology, Retrospective Studies, Lymph Nodes surgery, Lymph Nodes pathology, Lymph Node Excision, Neoplasm Staging, Hysterectomy, Uterine Cervical Neoplasms surgery, Uterine Cervical Neoplasms pathology
- Abstract
Objective: Lymph node metastases (pN+) in presumed early-stage cervical cancer negatively impact prognosis. Using federated learning, we aimed to develop a tool to identify a group of women at low risk of pN+, to guide the shared decision-making process concerning the extent of lymph node dissection., Methods: Women with cervical cancer between 2005 and 2020 were identified retrospectively from population-based registries: the Danish Gynaecological Cancer Database, Swedish Quality Registry for Gynaecologic Cancer and Netherlands Cancer Registry. Inclusion criteria were: squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma; The International Federation of Gynecology and Obstetrics 2009 IA2, IB1 and IIA1; treatment with radical hysterectomy and pelvic lymph node assessment. We applied privacy-preserving federated logistic regression to identify risk factors of pN+. Significant factors were used to stratify the risk of pN+., Results: We included 3606 women (pN+ 11%). The most important risk factors of pN+ were lymphovascular space invasion (LVSI) (odds ratio [OR] 5.16, 95% confidence interval [CI], 4.59-5.79), tumour size 21-40 mm (OR 2.14, 95% CI, 1.89-2.43) and depth of invasion>10 mm (OR 1.81, 95% CI, 1.59-2.08). A group of 1469 women (41%)-with tumours without LVSI, tumour size ≤20 mm, and depth of invasion ≤10 mm-had a very low risk of pN+ (2.4%, 95% CI, 1.7-3.3%)., Conclusion: Early-stage cervical cancer without LVSI, a tumour size ≤20 mm and depth of invasion ≤10 mm, confers a low risk of pN+. Based on an international privacy-preserving analysis, we developed a useful tool to guide the shared decision-making process regarding lymph node dissection., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
11. Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.
- Author
-
Wenzel HHB, Olthof EP, Bekkers RLM, Boere IA, Lemmens VEPP, Nijman HW, Stalpers LJA, van der Aa MA, van der Velden J, and Mom CH
- Subjects
- Chemoradiotherapy, Adjuvant, Female, Humans, Hysterectomy, Intraoperative Period, Lymph Node Excision, Lymphatic Metastasis, Randomized Controlled Trials as Topic, Treatment Outcome, Uterine Cervical Neoplasms drug therapy, Uterine Cervical Neoplasms radiotherapy, Lymph Nodes pathology, Lymph Nodes surgery, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms therapy
- Abstract
Upon discovery of lymph node metastasis during radical hysterectomy with pelvic lymphadenectomy in early-stage cervical cancer, the gynaecologist may pursue one of two treatment strategies: abandonment of surgery followed by primary (chemo)radiotherapy (PRT) or completion of radical hysterectomy, followed by adjuvant (chemo)radiotherapy (RHRT). Current guidelines recommend PRT over RHRT, as combined treatment is presumably associated with increased morbidity. However, this review of literature suggests there are no significant differences in survival and recurrence and total proportions of adverse events between treatment strategies. Additionally, both strategies are associated with varying types of adverse events, and affect quality of life and sexual functioning differently, both in the short and long term. Although total proportions of adverse events were comparable between treatment strategies, lower extremity lymphoedema was reported more often after RHRT and symptom experience (e.g. distress from bladder or bowel problems) and sexual dysfunction more often after PRT. As reporting of adverse events, quality of life and sexual functioning were not standardised across the articles included, and covariate adjustment was not conducted in most of the analyses, comparability of studies is hampered. Accumulating retrospective evidence suggests no major differences on oncological outcome and morbidity after PRT and RHRT for intraoperatively discovered lymph node metastasis in cervical cancer. However, conclusions should be considered cautiously, as all studies were of retrospective design with small sample sizes. Still, treatment strategies seem to affect adverse events, quality of life and sexual functioning in different ways, allowing room for shared decision-making and personalised treatment., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
12. No improvement in survival of older women with cervical cancer-A nationwide study.
- Author
-
Wenzel HHB, Bekkers RLM, Lemmens VEPP, Van der Aa MA, and Nijman HW
- Subjects
- Adolescent, Adult, Age Factors, Aged, Brachytherapy adverse effects, Brachytherapy mortality, Chemoradiotherapy adverse effects, Chemoradiotherapy mortality, Female, Humans, Middle Aged, Neoplasm Staging, Netherlands, Radiation Oncologists trends, Registries, Survival Rate trends, Time Factors, Treatment Outcome, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms pathology, Young Adult, Brachytherapy trends, Chemoradiotherapy trends, Oncologists trends, Practice Patterns, Physicians' trends, Uterine Cervical Neoplasms therapy
- Abstract
Aim: This study aims to report trends in primary treatment and survival in cervical cancer (CC) to identify opportunities to improve clinical practice and disease outcome., Methods: Patients diagnosed with CC between 1989 and 2018 were identified from the Netherlands Cancer Registry (N = 21,644). Trends in primary treatment and 5-year relative survival were analysed with the Cochran-Armitage trend test and multivariable Poisson regression, respectively., Results: In early CC, surgery remains the preferred treatment for ages 15-74. Overall, it was applied more often in younger than in older patients (92% in 15-44; 64% in 65-74). For 75+, surgery use was stable over time (38%-41%, p=0.368), while administration of radiotherapy decreased (57%-29%, p < 0.001). In locally advanced CC, chemoradiation use increased over time (5%-65%, p < 0.001). It was applied least often for 75+, in which radiotherapy remains most common (54% in 2014-2018). In metastatic CC, chemotherapy use increased over time (11%-28%, p < 0.001), but varied across age groups (6%-40% in 2014-2018). In patients treated with primary chemoradiation, regardless of stage, brachytherapy use increased over time (p ≤ 0.001). Full cohort 5-year survival increased from 68% to 74% (relative excess risk 0.55; 95% confidence interval [0.50-0.62]). Increases were most significant in locally advanced CC (38%-60%; 0.55 [0.47-0.65]). Survival remained stable in 75+ (38%-34%; 0.82 [0.66-1.02])., Conclusion: Relative survival for cervical cancer increased over the last three decades. The proportion of older patients receiving preferred treatment lags behind. Consequently, survival did not improve in the oldest patients., Competing Interests: Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: H.N. reports receiving grants from Aduro and DCprime and is founder and stockholder of ViciniVax. All the other authors do not have any conflict of interest to declare., (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
13. Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI?
- Author
-
Wenzel HHB, Van Kol KGG, Nijman HW, Lemmens VEPP, Van der Aa MA, Ebisch RMF, and Bekkers RLM
- Subjects
- Adult, Aged, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell therapy, Female, Humans, Lymphatic Metastasis, Middle Aged, Neoplasm Invasiveness, Retrospective Studies, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms therapy, Lymph Nodes pathology, Uterine Cervical Neoplasms pathology
- Abstract
Objective: Cervical cancer with ≤5 mm depth of invasion and >7 mm horizontal spread is classified FIGO IA instead of FIGO IB in the revised staging system, as horizontal spread is no longer considered. We aimed to determine the incidence of lymph node metastasis (LNM) and, consequently, the necessity of pelvic lymph node assessment., Methods: Patients diagnosed between January 2015 and May 2019 with cervical cancer FIGO (2009) stage IB with ≤5 mm depth of invasion and >7 mm horizontal spread, were identified from the Netherlands Cancer Registry. Associations between disease-characteristics and lymph node metastasis (LNM), and overall survival, were assessed., Results: Of 170 patients, six (3.5%) had LNM: 4/53 (7.6%) with adenocarcinoma and 2/117 (1.7%) with squamous cell carcinoma (p = .077). Four-year overall survival was 98.2%. LNM was observed more often in tumours with LVSI (4/43 patients, 9.3%) than without LVSI (2/117 patients, 1.7%) (p = .045). In adenocarcinoma with 3-5 mm depth of invasion LNM rate was 10% (4/40). None of the following tumours were observed with LNM: squamous cell carcinoma without LVSI (0/74); adenocarcinoma with <3 mm depth of invasion (0/13); <3 mm depth of invasion without LVSI (0/36)., Conclusions: Lymph node assessment is essential in any tumour with LVSI or in adenocarcinoma with 3-5 mm depth of invasion. It can be omitted in squamous cell carcinoma without LVSI, in adenocarcinoma with <3 mm depth of invasion and in any tumours without LVSI and with <3 mm depth of invasion., Competing Interests: Declaration of competing interest None of the authors received financial support for the research and/or authorship of this article. HN reports a grant from the Dutch Cancer Society for a therapeutic vaccine study in CIN3 patients and is stock holder/founder of Vicinivax. None of the other authors have any possible conflicts of interest to declare., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
14. Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review.
- Author
-
Wenzel HHB, Smolders RGV, Beltman JJ, Lambrechts S, Trum HW, Yigit R, Zusterzeel PLM, Zweemer RP, Mom CH, Bekkers RLM, Lemmens VEPP, Nijman HW, and Van der Aa MA
- Subjects
- Abdomen surgery, Adult, Aged, Cohort Studies, Female, Humans, Hysterectomy mortality, Hysterectomy statistics & numerical data, Middle Aged, Neoplasm Staging, Netherlands epidemiology, Registries, Retrospective Studies, Survival Analysis, Treatment Outcome, Uterine Cervical Neoplasms pathology, Hysterectomy methods, Laparoscopy methods, Laparoscopy mortality, Laparoscopy statistics & numerical data, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms surgery
- Abstract
Aim: Recently, the safety of laparoscopic radical hysterectomy (LRH) has been called into question in early-stage cervical cancer. This study aimed to evaluate overall survival (OS) and disease-free survival (DFS) in patients treated with abdominal radical hysterectomy (ARH) and LRH for early-stage cervical cancer and to provide a literature review., Methods: Patients diagnosed between 2010 and 2017 with International Federation of Gynaecology and Obstetrics (2009) stage IA2 with lymphovascular space invasion, IB1 and IIA1, were identified from the Netherlands Cancer Registry. Cox regression with propensity score, based on inverse probability treatment weighting, was applied to examine the effect of surgical approach on 5-year survival and calculate hazard ratios (HR) and 95% confidence intervals (CIs). Literature review included observational studies with (i) analysis on tumours ≤4 cm (ii) median follow-up ≥30 months (iii) ≥5 events per predictor parameter in multivariable analysis or a propensity score., Results: Of the 1109 patients, LRH was performed in 33%. Higher mortality (9.4% vs. 4.6%) and recurrence (13.1% vs. 7.3%) were observed in ARH than LRH. However, adjusted analyses showed similar DFS (89.4% vs. 90.2%), HR 0.92 [95% CI: 0.52-1.60]) and OS (95.2% vs. 95.5%), HR 0.94 [95% CI: 0.43-2.04]). Analyses on tumour size (<2/≥2 cm) also gave similar survival rates. Review of nine studies showed no distinct advantage of ARH, especially in tumours <2 cm., Conclusion: After adjustment, our retrospective study showed equal oncological outcomes between ARH and LRH for early-stage cervical cancer - also in tumours <2 cm. This is in correspondence with results from our literature review., Competing Interests: Conflict of interest statement H.N. reports receiving grants from Aduro and DCprime and is founder and stockholder of ViciniVax. All the other authors do not have any conflict of interest to declare., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.